Eli Lilly (NYSE:LLY) is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, ...
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that ...
Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...
The FDA has approved Eli Lilly's Ebglyss for moderate-to-severe eczema in patients 12 and older. The treatment is ...
Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...
Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...
Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...